X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 43.7 26.7 163.5% View Chart
P/BV x 3.6 2.8 130.8% View Chart
Dividend Yield % 0.4 1.0 34.7%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-17
DR. REDDYS LAB
Mar-16
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6224,383 14.2%   
Low Rs4582,750 16.7%   
Sales per share (Unadj.) Rs181.9920.1 19.8%  
Earnings per share (Unadj.) Rs12.9126.1 10.2%  
Cash flow per share (Unadj.) Rs29.3183.0 16.0%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.40.6 66.0%  
Book value per share (Unadj.) Rs155.7685.8 22.7%  
Shares outstanding (eoy) m804.51170.61 471.5%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.03.9 76.6%   
Avg P/E ratio x42.028.3 148.4%  
P/CF ratio (eoy) x18.419.5 94.5%  
Price / Book Value ratio x3.55.2 66.7%  
Dividend payout %15.515.9 98.0%   
Avg Mkt Cap Rs m434,516608,481 71.4%   
No. of employees `00023.021.7 106.3%   
Total wages/salary Rs m26,33831,874 82.6%   
Avg. sales/employee Rs Th6,349.17,244.4 87.6%   
Avg. wages/employee Rs Th1,143.01,470.9 77.7%   
Avg. net profit/employee Rs Th449.3992.8 45.3%   
INCOME DATA
Net Sales Rs m146,302156,978 93.2%  
Other income Rs m2,2872,693 84.9%   
Total revenues Rs m148,589159,671 93.1%   
Gross profit Rs m24,75834,587 71.6%  
Depreciation Rs m13,2299,705 136.3%   
Interest Rs m1,594824 193.4%   
Profit before tax Rs m12,22226,751 45.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7985,237 34.3%   
Profit after tax Rs m10,35421,514 48.1%  
Gross profit margin %16.922.0 76.8%  
Effective tax rate %14.719.6 75.1%   
Net profit margin %7.113.7 51.6%  
BALANCE SHEET DATA
Current assets Rs m87,370118,201 73.9%   
Current liabilities Rs m33,08168,368 48.4%   
Net working cap to sales %37.131.7 116.9%  
Current ratio x2.61.7 152.8%  
Inventory Days Days8760 145.0%  
Debtors Days Days6297 64.3%  
Net fixed assets Rs m111,56772,265 154.4%   
Share capital Rs m1,609853 188.6%   
"Free" reserves Rs m123,645111,548 110.8%   
Net worth Rs m125,254117,009 107.0%   
Long term debt Rs m36,45410,690 341.0%   
Total assets Rs m209,532200,104 104.7%  
Interest coverage x8.733.5 25.9%   
Debt to equity ratio x0.30.1 318.6%  
Sales to assets ratio x0.70.8 89.0%   
Return on assets %5.711.2 51.1%  
Return on equity %8.318.4 45.0%  
Return on capital %8.521.6 39.4%  
Exports to sales %34.246.3 74.0%   
Imports to sales %8.39.0 93.2%   
Exports (fob) Rs m50,05072,618 68.9%   
Imports (cif) Rs m12,20314,050 86.9%   
Fx inflow Rs m51,06675,405 67.7%   
Fx outflow Rs m17,67827,115 65.2%   
Net fx Rs m33,38848,290 69.1%   
CASH FLOW
From Operations Rs m23,82440,476 58.9%  
From Investments Rs m-13,127-19,421 67.6%  
From Financial Activity Rs m-13,239-17,009 77.8%  
Net Cashflow Rs m-2,4784,046 -61.2%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT LTD.  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON LTD  J.B.CHEMICALS  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

Sep 12, 2016

Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 21, 2017 02:40 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS